Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease.

摘要

We read with great interest the article by Lewindon et al., who demonstrated the importance of liver biopsies in the detection of cystic fibrosis-associated liver disease (CFLD). They demonstrated that in CF complications of portal hypertension can occur before die onset of cirrhosis as determined by liver biopsy. They could partially attribute this to sampling error, although a great effort was made to reduce sampling error by performing dual pass biopsies. However, we are not convinced that sampling error is the main issue. We believe, from Lewindon et al.1 and our own findings, that CFLD often presents as noncirrhotic portal hypertension (NCPH) in which the development of portal hypertension precedes that of cirrhosis.